APHA:CA:TSX-Aphria Inc (CAD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | TSX

Last Closing Price

CAD 15.82

Change

0.00 (0.00)%

Market Cap

CAD 5.01B

Volume

0.01B

Average Target Price

CAD 11.46 (-27.56%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Aphria Inc. cultivates, processes, produces, markets, distributes, and sells medical cannabis in Canada and internationally. The company offers pharmaceutical-grade medical cannabis, adult-use cannabis, and cannabis-derived extracts and derivative cannabis products under the Solei, RIFF, Good Supply, Aphria, P'tite Pof, and Broken Coast brands. It serves patients and consumers through distributors and online. The company is headquartered in Leamington, Canada. Address: 98 Talbot Street West, Leamington, ON, Canada, N8H 1M8

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-16 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
WEED:CA Canopy Growth Corporation

N/A

CAD15.82B N/A N/A
BHC:CA Bausch Health Companies Inc

N/A

CAD11.92B N/A 28.11
CRON:CA Cronos Group Inc

N/A

CAD4.97B 48.57 N/A
ACB:CA Aurora Cannabis Inc

N/A

CAD2.81B 1,171.00 N/A
HEXO:CA HEXO Corp

N/A

CAD1.12B N/A N/A
CWEB:CA Charlotte's Web Holdings, Inc

N/A

CAD0.85B 120.37 N/A
GUD:CA Knight Therapeutics Inc

N/A

CAD0.72B 27.69 7.22
OGI:CA OrganiGram Holdings Inc

N/A

CAD0.53B -99,999.99 N/A
HLS:CA HLS Therapeutics Inc

N/A

CAD0.52B N/A 40.85
RIV:CA Canopy Rivers Inc

N/A

CAD0.39B -99,999.99 4.88

ETFs Containing APHA:CA

Symbol Name Weight Mer Price(Change) Market Cap
HMMJ:CA Horizons Marijuana Life S.. 0.00 % 0.75 %

N/A

CAD0.42B
SEED:CA Evolve Marijuana Fund 0.00 % 0.75 %

N/A

CAD3.63M
HMMJ-U:CA Horizons Marijuana Life S.. 0.00 % 0.75 %

N/A

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 79.77% 96% A 100% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 79.77% 96% A 100% A+
Trailing 12 Months  
Capital Gain 129.94% 100% A+ 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 129.94% 100% A+ 96% A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -12.04% 48% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.04% 48% F 9% F
Risk Return Profile  
Volatility (Standard Deviation) 30.15% 74% C 26% F
Risk Adjusted Return -39.93% 48% F 17% F
Market Capitalization 5.01B 93% A 89% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 57.08 36% F 12% F
Price/Book Ratio 2.65 28% F 34% F
Price / Cash Flow Ratio -37.46 86% B 92% A-
EV/EBITDA 598.01 7% F 1% F
Management Effectiveness  
Return on Equity -11.82% 71% C- 27% F
Return on Invested Capital -2.80% 76% C 30% F
Return on Assets 0.24% 79% C+ 43% F
Debt to Equity Ratio 22.09% 45% F 74% C
Technical Ratios  
Short Ratio 1.62 59% F 39% F
Short Percent N/A N/A N/A N/A N/A
Beta 2.64 11% F 6% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector